vs
Apellis Pharmaceuticals, Inc.（APLS）与福尼克斯（PLAB）财务数据对比。点击上方公司名可切换其他公司
福尼克斯的季度营收约是Apellis Pharmaceuticals, Inc.的1.1倍（$210.4M vs $199.9M），福尼克斯净利率更高（10.9% vs -29.5%，领先40.4%），福尼克斯同比增速更快（-5.5% vs -5.9%），福尼克斯自由现金流更多（$25.2M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -3.8%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
福尼克斯是美国半导体光掩模制造商，2009年时位居全球第三大光掩模供应商，同时也是电子束产业倡议组织的成员，专注于为半导体行业提供关键的掩模产品，支撑芯片制造环节的图形转移需求。
APLS vs PLAB — 直观对比
营收规模更大
PLAB
是对方的1.1倍
$199.9M
营收增速更快
PLAB
高出0.4%
-5.9%
净利率更高
PLAB
高出40.4%
-29.5%
自由现金流更多
PLAB
多$39.5M
$-14.3M
两年增速更快
APLS
近两年复合增速
-3.8%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $210.4M |
| 净利润 | $-59.0M | $22.9M |
| 毛利率 | — | 33.7% |
| 营业利润率 | -25.6% | 22.9% |
| 净利率 | -29.5% | 10.9% |
| 营收同比 | -5.9% | -5.5% |
| 净利润同比 | -62.2% | -32.4% |
| 每股收益（稀释后） | $-0.40 | $0.39 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSPLAB
| Q4 25 | $199.9M | — | ||
| Q3 25 | $458.6M | $210.4M | ||
| Q2 25 | $178.5M | $211.0M | ||
| Q1 25 | $166.8M | $212.1M | ||
| Q4 24 | $212.5M | $222.6M | ||
| Q3 24 | $196.8M | $211.0M | ||
| Q2 24 | $199.7M | $217.0M | ||
| Q1 24 | $172.3M | $216.3M |
净利润APLSPLAB
| Q4 25 | $-59.0M | — | ||
| Q3 25 | $215.7M | $22.9M | ||
| Q2 25 | $-42.2M | $8.9M | ||
| Q1 25 | $-92.2M | $42.9M | ||
| Q4 24 | $-36.4M | $33.9M | ||
| Q3 24 | $-57.4M | $34.4M | ||
| Q2 24 | $-37.7M | $36.3M | ||
| Q1 24 | $-66.4M | $26.2M |
毛利率APLSPLAB
| Q4 25 | — | — | ||
| Q3 25 | — | 33.7% | ||
| Q2 25 | — | 36.9% | ||
| Q1 25 | — | 35.6% | ||
| Q4 24 | — | 37.0% | ||
| Q3 24 | — | 35.6% | ||
| Q2 24 | — | 36.5% | ||
| Q1 24 | — | 36.6% |
营业利润率APLSPLAB
| Q4 25 | -25.6% | — | ||
| Q3 25 | 48.7% | 22.9% | ||
| Q2 25 | -18.6% | 26.4% | ||
| Q1 25 | -50.0% | 24.6% | ||
| Q4 24 | -12.3% | 25.1% | ||
| Q3 24 | -24.0% | 24.7% | ||
| Q2 24 | -14.7% | 25.8% | ||
| Q1 24 | -36.0% | 26.6% |
净利率APLSPLAB
| Q4 25 | -29.5% | — | ||
| Q3 25 | 47.0% | 10.9% | ||
| Q2 25 | -23.6% | 4.2% | ||
| Q1 25 | -55.3% | 20.2% | ||
| Q4 24 | -17.1% | 15.2% | ||
| Q3 24 | -29.2% | 16.3% | ||
| Q2 24 | -18.9% | 16.7% | ||
| Q1 24 | -38.5% | 12.1% |
每股收益（稀释后）APLSPLAB
| Q4 25 | $-0.40 | — | ||
| Q3 25 | $1.67 | $0.39 | ||
| Q2 25 | $-0.33 | $0.15 | ||
| Q1 25 | $-0.74 | $0.68 | ||
| Q4 24 | $-0.30 | $0.54 | ||
| Q3 24 | $-0.46 | $0.55 | ||
| Q2 24 | $-0.30 | $0.58 | ||
| Q1 24 | $-0.54 | $0.42 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $575.8M |
| 总债务越低越好 | — | $16.0K |
| 股东权益账面价值 | $370.1M | $1.1B |
| 总资产 | $1.1B | $1.8B |
| 负债/权益比越低杠杆越低 | — | 0.00× |
8季度趋势，按日历期对齐
现金及短期投资APLSPLAB
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | $575.8M | ||
| Q2 25 | $370.0M | $558.4M | ||
| Q1 25 | $358.4M | $642.2M | ||
| Q4 24 | $411.3M | $640.7M | ||
| Q3 24 | $396.9M | $606.4M | ||
| Q2 24 | $360.1M | $559.9M | ||
| Q1 24 | $325.9M | $521.5M |
总债务APLSPLAB
| Q4 25 | — | — | ||
| Q3 25 | — | $16.0K | ||
| Q2 25 | — | $19.0K | ||
| Q1 25 | — | $21.0K | ||
| Q4 24 | — | $25.0K | ||
| Q3 24 | — | $28.0K | ||
| Q2 24 | — | $2.5M | ||
| Q1 24 | $93.1M | $2.7M |
股东权益APLSPLAB
| Q4 25 | $370.1M | — | ||
| Q3 25 | $401.2M | $1.1B | ||
| Q2 25 | $156.3M | $1.1B | ||
| Q1 25 | $164.2M | $1.1B | ||
| Q4 24 | $228.5M | $1.1B | ||
| Q3 24 | $237.1M | $1.1B | ||
| Q2 24 | $264.3M | $1.0B | ||
| Q1 24 | $266.7M | $1.0B |
总资产APLSPLAB
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | $1.8B | ||
| Q2 25 | $821.4M | $1.7B | ||
| Q1 25 | $807.3M | $1.7B | ||
| Q4 24 | $885.1M | $1.7B | ||
| Q3 24 | $901.9M | $1.6B | ||
| Q2 24 | $904.5M | $1.6B | ||
| Q1 24 | $831.9M | $1.6B |
负债/权益比APLSPLAB
| Q4 25 | — | — | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | 0.00× | ||
| Q1 25 | — | 0.00× | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.00× | ||
| Q1 24 | 0.35× | 0.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $50.1M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $25.2M |
| 自由现金流率自由现金流/营收 | -7.1% | 12.0% |
| 资本支出强度资本支出/营收 | 0.1% | 11.8% |
| 现金转化率经营现金流/净利润 | — | 2.19× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $64.5M |
8季度趋势，按日历期对齐
经营现金流APLSPLAB
| Q4 25 | $-14.2M | — | ||
| Q3 25 | $108.5M | $50.1M | ||
| Q2 25 | $4.4M | $31.5M | ||
| Q1 25 | $-53.4M | $78.5M | ||
| Q4 24 | $19.4M | $68.4M | ||
| Q3 24 | $34.1M | $75.1M | ||
| Q2 24 | $-8.3M | $76.5M | ||
| Q1 24 | $-133.0M | $41.5M |
自由现金流APLSPLAB
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | $25.2M | ||
| Q2 25 | $4.4M | $-29.1M | ||
| Q1 25 | $-53.4M | $43.3M | ||
| Q4 24 | $19.3M | $25.2M | ||
| Q3 24 | — | $50.7M | ||
| Q2 24 | $-8.4M | $56.5M | ||
| Q1 24 | $-133.3M | $-1.8M |
自由现金流率APLSPLAB
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | 12.0% | ||
| Q2 25 | 2.5% | -13.8% | ||
| Q1 25 | -32.0% | 20.4% | ||
| Q4 24 | 9.1% | 11.3% | ||
| Q3 24 | — | 24.0% | ||
| Q2 24 | -4.2% | 26.0% | ||
| Q1 24 | -77.3% | -0.8% |
资本支出强度APLSPLAB
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | 11.8% | ||
| Q2 25 | 0.0% | 28.7% | ||
| Q1 25 | 0.0% | 16.6% | ||
| Q4 24 | 0.0% | 19.4% | ||
| Q3 24 | 0.0% | 11.6% | ||
| Q2 24 | 0.0% | 9.2% | ||
| Q1 24 | 0.2% | 20.0% |
现金转化率APLSPLAB
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | 2.19× | ||
| Q2 25 | — | 3.55× | ||
| Q1 25 | — | 1.83× | ||
| Q4 24 | — | 2.02× | ||
| Q3 24 | — | 2.18× | ||
| Q2 24 | — | 2.11× | ||
| Q1 24 | — | 1.59× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
PLAB
| High End Integrated Circuits | $53.6M | 25% |
| High End Flat Panel Displays | $53.5M | 25% |
| KR | $43.7M | 21% |
| Other | $42.1M | 20% |
| Mainstream Flat Panel Displays | $9.1M | 4% |
| Transferred At Point In Time | $8.4M | 4% |
